Evaluating Subcutaneous Immunoglobulin Therapy in CIDP

This episode, titled "Evaluating Subcutaneous Immunoglobulin Therapy in CIDP," features panelists reviewing the clinical trial data underpinning subcutaneous immunoglobulin use in CIDP and sharing practical guidance on identifying the right patients for this treatment approach. The discussion opens with a review of the evidence base, beginning with a study of 20% subcutaneous immunoglobulin that demonstrated superiority over placebo for maintaining treatment benefit in IVIG responders. A second subcutaneous immunoglobulin study, conducted during the COVID-19 pandemic, did not meet its primary endpoint due to recruitment and retention challenges, but demonstrated supportive evidence of benefit and received FDA approval based on its established efficacy in immunodeficiency and other autoimmune conditions. Both subcutaneous products are characterized as effective, FDA-approved maintenance therapy options.

Panelists then discuss the clinical profiles that favor subcutaneous immunoglobulin, identifying several key candidate groups: patients experiencing IVIG-related side effects such as headaches and nausea, those burdened by frequent infusion center visits, patients with difficult intravenous access for whom a port would otherwise be considered, and patients experiencing end-of-cycle wearing off with IVIG. The more stable immunoglobulin levels achieved with subcutaneous administration are highlighted as particularly advantageous for the latter group, producing a smoother pharmacokinetic profile without the peak-and-trough fluctuations associated with intravenous infusions. Additional benefits noted include a lower incidence of systemic adverse effects and potentially fewer thrombotic complications.

Conversely, panelists identify IVIG as preferable for patients who are unable or unwilling to self-administer therapy, noting that the reliability of a clinician- or nurse-administered infusion is an important practical consideration. The facilitated subcutaneous immunoglobulin option is highlighted as a middle ground, allowing administration by an infusion nurse on a three-to-four week schedule without requiring self-administration. Panelists conclude that the choice between intravenous and subcutaneous immunoglobulin should be individualized through shared decision-making, noting that as long as the correct dose is achieved, both routes are supported by evidence and can effectively manage CIDP.

In the next episode, "Emerging Targeted Therapies in CIDP," panelists will examine the mechanism of action and clinical evidence for FcRn antagonists as a targeted treatment approach in CIDP, discuss strategies for identifying appropriate candidates, and share practical guidance on safely transitioning patients from immunoglobulin therapy to FcRn antagonists while minimizing relapse risk.